重症医学科医师配置与ICU死亡率及成本效益的日本全国观察性研究
该回顾性观察研究利用日本全国行政数据库,纳入2020年4月至2021年3月入住ICU的患者,按每日收费类别分为高配置ICU(ICU1/2,n=71,412)和低配置ICU(ICU3/4,n=46,330)两组。结果显示,ICU1/2组ICU死亡率2.6%低于ICU3/4组4.3%(p<0.001),院内死亡率6.1%低于8.9%(p<0.001)。ICU1/2组人均费用2,249,270±1,955,953日元,高于ICU3/4组的1,682,546±1,588,928日元,差值为566,724日元。增量成本效果比(ICER)为718,659日元/QALY,低于500万日元/QALY的成本效益阈值。结论认为ICU1/2与更低的ICU患者死亡率相关,且治疗较ICU3/4更具成本效益。
要点
- 高配置ICU(ICU1/2)组ICU死亡率为2.6%,低配置ICU(ICU3/4)组为4.3%,差异有统计学意义(p<0.001)。
- 高配置ICU(ICU1/2)组院内死亡率为6.1%,低配置ICU(ICU3/4)组为8.9%,差异有统计学意义(p<0.001)。
- 高配置ICU(ICU1/2)组人均费用为2,249,270±1,955,953日元,低配置ICU(ICU3/4)组为1,682,546±1,588,928日元,差值为566,724日元。
- 增量成本效果比(ICER)为718,659日元/QALY,低于500万日元/QALY的成本效益阈值。
- 该研究为回顾性观察性研究,利用日本全国行政数据库,纳入2020年4月至2021年3月入住ICU的患者。
适用人群与场景
- 2020年4月至2021年3月入住日本ICU的患者,分为ICU1/2组(n=71,412;60.7%)和ICU3/4组(n=46,330;39.3%)。
诊断标准与关键阈值
- 日本ICU按每日管理费分为四类:ICU管理费1和2(ICU1/2,相当于高配置)与3和4(ICU3/4,相当于低配置)。
研究设计与关键结果
- 研究类型:回顾性观察性研究,利用日本全国行政数据库,纳入2020年4月至2021年3月入住ICU的患者。
- 主要终点:ICU死亡率ICU1/2组2.6% vs ICU3/4组4.3%(p<0.001);院内死亡率ICU1/2组6.1% vs ICU3/4组8.9%(p<0.001)。
- 成本:人均费用ICU1/2组2,249,270±1,955,953日元 vs ICU3/4组1,682,546±1,588,928日元,差值566,724日元。
- 增量成本效果比(ICER)为718,659日元/QALY,低于500万日元/QALY的成本效益阈值。
证据类型、等级与局限
- 证据类型:回顾性观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论:ICU1/2与更低的ICU患者死亡率相关,且治疗较ICU3/4更具成本效益(ICER<500万日元/QALY)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Japan has four types of intensive care units (ICUs) that are divided into two categories according to the management fee charged per day: ICU management fees 1 and 2 (ICU1/2) (equivalent to high-intensity staffing) and 3 and 4 (ICU3/4) (equivalent to low-intensity staffing). Although ICU1/2 charges a higher rate than ICU3/4, no cost-effectiveness analysis has been performed for ICU1/2. This study evaluated the clinical outcomes and cost-effectiveness of ICU1/2 compared with those of ICU3/4.
METHODS: This retrospective observational study used a nationwide Japanese administrative database to identify patients admitted to ICUs between April 2020 and March 2021 and divided them into the ICU1/2 and ICU3/4 groups. The ICU mortality rates and in-hospital mortality rates were determined, and the incremental cost-effectiveness ratio (ICER) (Japanese Yen (JPY)/QALY), defined as the difference between quality-adjusted life year (QALY) and medical costs, was compared between ICU1/2 and ICU3/4. Data analysis was performed using the Chi-squared test; an ICER of < 5 million JPY/QALY was considered cost-effective.
RESULTS: The ICU1/2 group (n = 71,412; 60.7%) had lower ICU mortality rates (ICU 1/2: 2.6% vs. ICU 3/4: 4.3%, p < 0.001) and lower in-hospital mortality rates (ICU 1/2: 6.1% vs. ICU 3/4: 8.9%, p < 0.001) than the ICU3/4 group (n = 46,330; 39.3%). The average cost per patient of ICU1/2 and ICU3/4 was 2,249,270 ± 1,955,953 JPY and 1,682,546 ± 1,588,928 JPY, respectively, with a difference of 566,724. The ICER was 718,659 JPY/QALY, which was below the cost-effectiveness threshold.
CONCLUSIONS: ICU1/2 is associated with lower ICU patient mortality than ICU3/4. Treatments under ICU1/2 are more cost-effective than those under ICU3/4, with an ICER of < 5 million JPY/QALY.
参考来源
- Ikumi S, Shiga T, Ueda T, et al. Intensive care unit mortality and cost-effectiveness associated with intensivist staffing: a Japanese nationwide observational study. J Intensive Care. 2023. PMID: 38049894. doi:10.1186/s40560-023-00708-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。